![Jean-Yves Nothias](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean-Yves Nothias
Fondateur chez
Vesale Partners SAS
Profil
Mr. Jean-Yves Nothias leads the Biotechnology Team at SGAM Alternative Investments.
He oversees all portfolio companies and has made significant contributions by bringing in CEOs, syndicating financial rounds and providing strategic advice.
Previously, he was a biotechnology analyst for Hambrecht & Quist based in Paris.
He worked at F.
Hoffmann-La Roche (US) and several scientific institutions in France and in the US.
Mr. Nothias holds a PhD in molecular biology from Université Paris VI and a masters degree in management from Université Paris Sorbonne.
Postes actifs de Jean-Yves Nothias
| Sociétés | Poste | Début |
|---|---|---|
Vesalius Biocapital Partners SARL
 Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners invests in companies located in Europe. The firm targets companies operating in the fields of life science, therapeutics, medical devices and diagnostics sectors. It provides financing for seed, early and later stage capital requirements with an investment size of up to USD 10 million. It acts as a lead & co-investor and acquires majority interest and also takes a seat on the board of directors. | Private Equity Investor | 01/12/2011 |
Vesale Partners SAS | Fondateur | 01/01/2012 |
FCPR Biotechnology Fund | Corporate Officer/Principal | - |
Anciens postes connus de Jean-Yves Nothias
| Sociétés | Poste | Fin |
|---|---|---|
| GENOMIC VISION | Directeur/Membre du Conseil | 24/07/2016 |
| SCYNEXIS, INC. | Directeur/Membre du Conseil | 04/06/2015 |
Amundi Private Equity Funds SA
 Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity invests in companies located in France. The firm targets companies operating in the fields of technology, demographics, and environment. It provides financing for growth and buyout stage capital requirements. It also acquires minority or majority interest and it takes board seat. | Director of Investments | 01/08/2011 |
Société Générale Asset Mgmt Alternative Invt (Private Equity)
 Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Head-Equity Investments | 07/04/2009 |
Gene-IT, Inc.
 Gene-IT, Inc. Packaged SoftwareTechnology Services Provides software solutions to life-science research organizations | Directeur/Membre du Conseil | 25/09/2007 |
Formation de Jean-Yves Nothias
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
Gene-IT, Inc.
Gene-IT, Inc. Packaged SoftwareTechnology Services Provides software solutions to life-science research organizations | Technology Services |
GQ Life Sciences, Inc.
 GQ Life Sciences, Inc. Packaged SoftwareTechnology Services Provides software solutions to life science research organizations | Technology Services |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Université de Paris IV Paris-Sorbonne
 Université de Paris IV Paris-Sorbonne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Pierre et Marie Curie
 Université Pierre et Marie Curie Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Picometrics SA
 Picometrics SA Electronic Equipment/InstrumentsElectronic Technology Manufactures Laser Induced Fluorescence (LIF) detectors | Electronic Technology |
Trod Medical NV
 Trod Medical NV Medical SpecialtiesHealth Technology Develops and commercializes tools for use in the focal ablation of soft tissues | Health Technology |
Société Générale Asset Mgmt Alternative Invt (Private Equity)
Société Générale Asset Mgmt Alternative Invt (Private Equity) Investment ManagersFinance SGAM AI/PE utilizes a top down investment approach drawing on the group's team of economists and analysts in addition to external research sources. They align the interest of their teams and the management of portfolio firms with those of their investors. They deploy their technical, sector, financial and managerial expertise in the private equity transactions. They are active private equity investment managers through board membership of their portfolio firms. SGAM AI/PE's venture capital investments are made up of new technologies, biotech and cardio-vascular focused investments. In information technology and engineering sciences, they generally seek early-stage investments initially between €750 thousand and €2.5 billion. Their strategy is to lead or co-lead investment rounds. They target firms in France and Europe in semi-conductors, networks and communications, digital media, software, environment, clean energy and other related industries such as aeronautics, automotive, etc. They look for experienced management teams, market leaders within a large market, rapidly scalable business models, high-level entry barriers, and sustainable competitive advantage with an exit strategy in five years. SGAM AI/PE's biotechnology investments are allocated in varying stages with a third in seed finance, a third in first round and the remainder in second or third round or later financing. The biotech team manages several different investment vehicles. Their investment portfolio is spread across Europe, in particular France, and the US. The investment size typically ranges from €1 million to €10 million. Within the sector, they focus on a wide variety of technologies such as companion diagnostics, regenerative medicine, bio-analysis tools, pharmaceutical manufacturing process technology, predictive in vivo modeling, genomics and proteomics and in silico chemistry tools. SGAM AI/PE's French SME team provides equity finance for unlisted small- and mid-sized firms in France with enterprise values between €5 million to €6 million for expansion capital and minority buyouts. They manage two different funds invested by both private and institutional investors. SGAM AI/PE's fund of funds group manages investments in venture capital, LBOs, turnaround, mezzanine and distressed debt funds in the US, UK, Europe and Asia. | Finance |
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services Develops and markets molecular diagnostic tests for cancer | Commercial Services |
Vesalius Biocapital Partners SARL
Vesalius Biocapital Partners SARL Investment ManagersFinance Vesalius Biocapital Partners invests in companies located in Europe. The firm targets companies operating in the fields of life science, therapeutics, medical devices and diagnostics sectors. It provides financing for seed, early and later stage capital requirements with an investment size of up to USD 10 million. It acts as a lead & co-investor and acquires majority interest and also takes a seat on the board of directors. | Finance |
Génomic Vision SA
 Génomic Vision SA Medical SpecialtiesHealth Technology Develops diagnostic tools using deoxyribonucleic acid analysis | Health Technology |
BioSystems International SAS
 BioSystems International SAS BiotechnologyHealth Technology Produces drugs and provides research services | Health Technology |
InGen Biosciences SA
 InGen Biosciences SA Medical SpecialtiesHealth Technology Develops in-vitro diagnostic products | Health Technology |
Amundi Private Equity Funds SA
Amundi Private Equity Funds SA Investment ManagersFinance Amundi Private Equity invests in companies located in France. The firm targets companies operating in the fields of technology, demographics, and environment. It provides financing for growth and buyout stage capital requirements. It also acquires minority or majority interest and it takes board seat. | Finance |
FCPR Biotechnology Fund | |
Vesale Partners SAS |
